CADLCandel Therapeutics, Inc.
$9.66+72% 1Y
$9.66
$4.4252 weeks$13.76
CADL in its own filings
CADL's filing record carries one kind of hard flag, each is shown beside the share of the whole market carrying the same one, because more than half of all companies carry at least one.
129
Events found in the filings · across 416 filings · the record starts in 2021
- Hard flags
- 1
Hard flags
- Most recent filing
- Sep 10, 2026
Most recent filing · Form 8-K
- Record starts
- Mar 15, 2021
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 12, 2026
- Delisting notice / listing-rule failurepast_3y
- 2023-11-21
- SEC comment-letter activity15 occurrences
- 2025-08-20
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 10, 2026On September 6, 2026, the Board of Directors (the “Board”) of Candel Therapeutics, Inc. (the “Company”) increased the size of the Board from ten (10) to eleven (11) directors and unanimously appointed Martine Zimmermann, Pharm.D, to fill the newly created vacancy on the Board, effective September 8, 2026.Director or officer change · Form 8-K
- Aug 13, 2026Candel Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights.Earnings release · press release
- Jun 16, 2026On June 12, 2026, Candel Therapeutics, Inc. (the “Company”) entered into an employment agreement (the “Employment Agreement”) with Charles Schoch, the Company’s Chief Financial Officer.Director or officer change · Form 8-K
- May 15, 2026AUA Investor Call Extended Data from.Regulation FD disclosure · press release
- May 14, 2026Candel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights.Earnings release · press release
- Mar 12, 2026Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights.Earnings release · press release
- Feb 23, 2026On February 19, 2026, Candel Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Citigroup Global Markets Inc., Cantor Fitzgerald & Co., and Stifel, Nicolaus & Company, Incorporated, as representatives (the “Representatives”) of the underwriters named therein …Material agreement entered · Form 8-K
- Feb 19, 2026On February 19, 2026, Candel Therapeutics, Inc. (the “Company”) announced its entry into a purchase and sale agreement (the “Purchase Agreement”) with funds managed by RTW Investments, LP (the “Purchaser”)Material agreement entered · Form 8-K
- Dec 5, 2025Forward-looking statements This presentation contains forward-looking.Regulation FD disclosure · press release
- Nov 13, 2025Candel Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…